1. Introduction

Cost-Utility Analysis (CUA) of biologics is an important component of pharmaceutical law, healthcare economics, bioethics, public health regulation and intellectual property governance. It provides a systematic framework for determining whether the additional clinical benefits offered by biological medicines justify their additional financial costs.

Biologics are medicinal products derived from living organisms or biological systems. Unlike conventional small-molecule medicines, they are generally produced through complex biological processes and may involve living cells, recombinant DNA technology, monoclonal antibodies, therapeutic proteins, vaccines and gene-based technologies.

Examples include:

Monoclonal antibodies used in cancer treatment.

Insulin and other recombinant therapeutic proteins.

Biological medicines used for autoimmune diseases.

Blood-derived medicinal products.

Advanced biological therapies, including certain gene and cell therapies.

Biosimilars developed to provide alternatives to reference biologics.

Many biologics offer substantial therapeutic benefits, particularly in diseases where conventional medicines provide inadequate results. However, their high development, manufacturing, storage and treatment costs create difficult questions concerning affordability, healthcare-resource allocation and equitable access.

Cost-Utility Analysis addresses these questions by comparing the additional costs of a biological medicine with the additional health benefits it produces.

Its central question is:

Does the additional improvement in patients' quality of life and survival justify the additional expenditure required to provide the biological treatment?

Importantly, CUA is not simply a method of reducing healthcare expenditure. It is also a mechanism for promoting rational, transparent and equitable healthcare decision-making.

2. Meaning and Conceptual Foundations

Cost-Utility Analysis is a form of economic evaluation that measures health outcomes in terms of both the quantity and quality of life.

Unlike a simple cost comparison, CUA examines whether a treatment produces meaningful improvements in:

Life expectancy.

Quality of life.

Reduction in disease-related disability.

Prevention of complications.

Improvement in functional independence.

Reduction in hospitalization.

Patient-reported health outcomes.

The principal measurement used in CUA is the Quality-Adjusted Life Year (QALY).

A QALY combines the duration of life with the quality of health experienced during that period.

For example, one year spent in perfect health generally represents one QALY, whereas one year spent in a health state assigned a utility value of 0.5 represents 0.5 QALYs.

The utility score generally ranges from:

1: Perfect health.

0: A health state equivalent to death.

Below 0: Certain health states considered worse than death.

These values depend on the valuation methodology and population preferences.

3. Mathematical Framework of Cost-Utility Analysis

The principal formula is the Incremental Cost-Effectiveness Ratio (ICER).

\[ ICER=\frac{C_1-C_0}{Q_1-Q_0} \]

Where:

\(C_1\) = Cost of biological treatment.

\(C_0\) = Cost of comparator treatment.

\(Q_1\) = QALYs achieved through biological treatment.

\(Q_0\) = QALYs achieved through comparator treatment.

Illustration:

Suppose a biological medicine costs ₹12 lakh per patient and produces 4 additional QALYs compared with conventional treatment costing ₹4 lakh.

\[ ICER=\frac{12,00,000-4,00,000}{4} \]

\[ ICER=₹2,00,000 \text{ per QALY} \]

This means that the healthcare system spends an additional ₹2 lakh for each additional QALY gained through the biological medicine.

The ICER must then be interpreted against an appropriate willingness-to-pay threshold, budget constraints, disease severity and distributive-justice considerations.

A lower ICER does not automatically establish that a treatment is affordable, and a higher ICER does not necessarily establish that it should be rejected.

4. Why Cost-Utility Analysis Is Particularly Important for Biologics

Biological medicines create economic challenges that are different from those associated with conventional pharmaceuticals.

A. High manufacturing costs

Biologics require sophisticated manufacturing infrastructure, including:

Cell-culture facilities.

Bioreactors.

Protein purification systems.

Sterile manufacturing environments.

Advanced quality-control laboratories.

Cold-chain transportation and storage.

Manufacturing costs can influence the final price of treatment.

B. Complex regulatory requirements

Biologics require extensive evaluation of safety, purity, potency, immunogenicity and manufacturing consistency.

Biosimilar development also requires a demonstration of similarity to the reference biological medicine, supported by appropriate analytical and clinical evidence.

These regulatory requirements influence development expenditure and market-entry timelines.

C. Long-term treatment expenditure

Certain biologics require repeated administration over several years. Consequently, the total cost of treatment may be considerably higher than the initial acquisition price suggests.

D. Uncertain long-term effectiveness

Some biologics have limited long-term clinical evidence at the time of market authorization.

Economic evaluations must therefore estimate long-term survival, disease progression, treatment discontinuation and adverse events.

E. Biosimilar competition

Biosimilars may reduce treatment costs by introducing competition into biological medicine markets.

However, lower acquisition prices do not automatically establish equivalent total economic value. Switching costs, monitoring requirements, administration expenses and clinical outcomes must also be considered.

5. Principal Components of Cost-Utility Analysis

5.1 Direct medical costs

These include:

Purchase price of biological medicines.

Hospital administration expenses.

Laboratory investigations.

Diagnostic procedures.

Medical consultations.

Management of adverse reactions.

Hospitalization and emergency treatment.

5.2 Direct non-medical costs

These include:

Transportation to treatment centres.

Accommodation.

Patient and caregiver travel expenses.

Additional expenses associated with repeated hospital visits.

5.3 Indirect costs

These include:

Lost working days.

Reduced productivity.

Caregiver absenteeism.

Premature retirement.

Economic consequences of long-term disability.

5.4 Intangible consequences

Certain consequences are difficult to quantify financially, including:

Pain and suffering.

Psychological distress.

Fear of disease progression.

Loss of independence.

Deterioration in social functioning.

Although these factors may not always be included directly in conventional QALY calculations, they remain important in broader healthcare evaluations.

6. Methodology for Evaluating Biological Medicines

A comprehensive cost-utility assessment should follow a structured methodology.

Step 1: Identification of the treatment population

The evaluator identifies the disease, patient population, severity, clinical characteristics and treatment eligibility.

Step 2: Selection of comparator

The biological medicine should be compared against relevant existing treatments, including conventional medicines, alternative biologics and biosimilars where appropriate.

Step 3: Collection of clinical evidence

Evidence should be obtained from randomized controlled trials, systematic reviews, meta-analyses and relevant real-world studies.

Step 4: Measurement of health utilities

Validated instruments such as EQ-5D-5L can be used to measure health-related quality of life.

Step 5: Estimation of treatment costs

All relevant treatment, monitoring, administration and adverse-event costs should be calculated.

Step 6: Calculation of incremental QALYs

The additional quality-adjusted survival attributable to the biological medicine is estimated.

Step 7: Calculation of ICER

The incremental cost is divided by incremental QALYs.

Step 8: Sensitivity analysis

The evaluator tests whether the results change when assumptions concerning drug prices, treatment duration, survival benefits or utility scores change.

Step 9: Equity and affordability assessment

The final decision should consider disease severity, vulnerable populations, budgetary limitations and access to alternative treatments.

7. Cost-Utility Analysis of Biologics in India

India presents a particularly important setting for the legal and economic evaluation of biological medicines because of its large population, unequal healthcare access, significant out-of-pocket expenditure and developing biosimilar industry.

7.1 Health Technology Assessment in India

The Government of India established the Health Technology Assessment in India (HTAIn) under the Department of Health Research.

Its institutional purpose is to generate evidence concerning:

Clinical effectiveness.

Economic effectiveness.

Safety.

Affordability.

Healthcare-resource allocation.

Equity in access to health technologies.

HTAIn evaluates medicines, medical devices, diagnostic technologies and healthcare interventions.

Health Technology Assessment in India (HTAIn)+1

The Indian Reference Case for economic evaluation recommends:

Cost-utility analysis as the preferred economic evaluation method.

QALYs as the preferred measure of health outcomes.

An abridged societal perspective for the base-case evaluation.

A 3% discount rate for costs and health outcomes.

Sensitivity analysis using alternative assumptions.

Distributional or extended cost-effectiveness analysis where appropriate.

An important qualification is that India does not have a formally established, universally recognised cost-effectiveness threshold in this reference framework. Therefore, researchers should not treat an arbitrary international QALY threshold as an automatically binding Indian legal standard.

PMC

7.2 Relevance to the Indian biosimilar industry

India has developed significant capabilities in biosimilar manufacturing.

However, biosimilar production requires considerable investment in research, analytical development, clinical evaluation and manufacturing infrastructure.

A 2024 study of six Indian biopharmaceutical companies estimated development costs of approximately US$18 million for microbial-system biosimilars and US$21 million for mammalian-system biosimilars, in addition to substantial capital investment. These are study-specific estimates, not universal industry costs.

Wiley Online Library

The legal challenge is to balance:

Innovation incentives.

Affordable pricing.

Regulatory compliance.

Patient safety.

Competitive market entry.

Public healthcare expenditure.

8. Indian Legal and Constitutional Framework

A. Constitution of India

Article 21 – Right to Life

The right to life has been judicially interpreted to include important dimensions of human dignity and access to healthcare.

In the context of biologics, Article 21 provides a constitutional foundation for examining whether unreasonable financial and institutional barriers prevent patients from accessing essential treatment.

Article 14 – Equality Before Law

Healthcare-resource allocation must not be arbitrary or discriminatory.

For example, decisions concerning access to expensive biological medicines should employ rational criteria rather than unjustified distinctions between similarly situated patients.

Article 47 – Public Health

Article 47 directs the State to regard improvement of public health as among its primary duties.

It provides an important constitutional basis for policies promoting affordable medicines and rational healthcare expenditure.

B. Drugs and Cosmetics Act, 1940

The Drugs and Cosmetics Act provides the principal statutory framework governing the import, manufacture, distribution and sale of drugs in India.

Biological products must comply with applicable regulatory requirements concerning quality, safety and efficacy.

C. New Drugs and Clinical Trials Rules, 2019

These Rules regulate clinical trials and the approval of new drugs, subject to applicable provisions and subsequent amendments.

For biological medicines, regulatory scrutiny is particularly important because manufacturing changes can influence product characteristics.

D. Biologicals and Biosimilars Regulatory Guidelines

India's regulatory framework includes the Guidelines on Similar Biologics: Regulatory Requirements for Marketing Authorization in India, 2016.

These guidelines address comparability, quality assessment, non-clinical studies, clinical evidence and post-marketing surveillance.

E. Patents Act, 1970

The Patents Act affects the economic accessibility of patented medicines.

Relevant provisions include:

Section 3(d): Limits patentability of certain new forms of known substances unless the statutory efficacy requirement is met.

Section 48: Defines patent-holder rights.

Section 84: Provides for compulsory licensing on specified statutory grounds.

Section 92: Provides for compulsory licensing in circumstances specified by the Act.

These provisions influence market competition, pricing and the availability of alternative treatments.

9. Important Case Laws Relating to Cost-Utility Analysis and Biologics

There is an important distinction in this area: courts have addressed the affordability of medicines, rationing of expensive treatments, patent protection and the legality of healthcare funding decisions. However, Indian courts have not established a comprehensive judicial formula requiring every biological medicine to pass a QALY-based cost-utility test.

The following cases are relevant to the legal foundations of the subject.

9.1 Rogers v. Swindon NHS Primary Care Trust [2006] EWCA Civ 392

Directly relevant to biologics

Facts:

The claimant, Ann Marie Rogers, suffered from HER2-positive breast cancer. Her treating clinician recommended trastuzumab (Herceptin), a monoclonal antibody.

The NHS Primary Care Trust refused to fund the treatment under its funding policy.

Legal issue:

Whether the healthcare authority could lawfully refuse access to a prescribed biological medicine through an irrational or inconsistently applied funding policy.

Judgment:

The Court of Appeal held that the funding policy was irrational because the authority had decided to fund treatment for certain patients while relying on exceptional circumstances that did not provide a rational basis for distinguishing between clinically comparable patients.

The refusal was quashed.

Legal principles:

Healthcare funding decisions must satisfy rationality requirements.

Clinical eligibility must be considered fairly.

Authorities must avoid arbitrary distinctions between comparable patients.

Cost and resource considerations must be addressed rationally.

Individual patient circumstances cannot be used as an unjustified substitute for clinically relevant criteria.

Relevance to CUA:

This case is particularly important because it concerned an expensive biological medicine.

It demonstrates that economic considerations cannot be applied through arbitrary or discriminatory funding policies. Cost-utility analysis may assist healthcare authorities in developing rational allocation criteria, but the analysis must be transparent and applied consistently.

Bailii

9.2 Servier Laboratories Ltd v National Institute for Health and Clinical Excellence [2009] EWHC 281 (Admin)

Facts:

Servier challenged NICE's technology appraisal concerning the cost-effectiveness of medicines for osteoporosis.

Legal issue:

Whether NICE's technology appraisal methodology and decision-making process were legally defective.

Judgment:

The High Court considered the use of cost-per-QALY analysis in the assessment of healthcare technologies.

The judgment discussed the importance of consistent cost-effectiveness standards and the consideration of relevant patient-group circumstances.

It explained the role of cost per QALY as a common benchmark for evaluating different healthcare interventions.

Relevance to biologics:

The judgment provides a legal framework for understanding how economic assessments of high-cost medicines can be incorporated into public healthcare decisions.

It also demonstrates that economic evaluation is not merely a mathematical exercise: the underlying methodology and decision-making process must be legally defensible.

Bailii

9.3 Servier Laboratories Ltd v NICE [2010] EWCA Civ 346

Legal issue:

The Court of Appeal considered the legal challenge to NICE's technology appraisal and the institutional role of NICE in evaluating healthcare interventions.

Principle:

Healthcare authorities must make decisions within their lawful powers, applying appropriate appraisal procedures and considering relevant evidence.

Relevance:

This case supports the importance of procedural legality in cost-utility evaluations, particularly where an adverse reimbursement decision affects access to expensive medicines.

Bailii

9.4 Paschim Banga Khet Mazdoor Samity v. State of West Bengal (1996) 4 SCC 37

Important Indian constitutional precedent

Facts:

A seriously injured person was denied timely medical treatment because government hospitals failed to provide the necessary facilities.

Legal issue:

Whether the State's failure to provide timely medical assistance violated Article 21.

Judgment:

The Supreme Court held that the State has a constitutional obligation to provide adequate medical facilities and that failure to provide timely medical treatment can violate the right to life.

The Court also emphasized the responsibility of the State to allocate adequate resources for medical services.

Relevance to biologics:

The judgment provides a constitutional foundation for examining the affordability and availability of essential biological medicines.

It does not establish an unconditional right to every expensive medicine. Nevertheless, it requires healthcare policies to be examined against the State's constitutional responsibilities.

calcuttahighcourt.gov.in+1

9.5 Novartis AG v. Union of India (2013) 6 SCC 1

Facts:

Novartis sought patent protection for an improved form of imatinib mesylate, marketed as Glivec, a cancer medicine.

Legal issue:

Whether the claimed modification satisfied the patentability requirements under Section 3(d) of the Patents Act, 1970.

Judgment:

The Supreme Court upheld the rejection of the patent application because the claimed invention did not satisfy the enhanced therapeutic-efficacy requirement under Section 3(d).

Relevance to biologics:

Although imatinib is a small-molecule drug and not a biologic, the decision is important for understanding the relationship between pharmaceutical innovation, patent protection and public access to medicines.

The decision also illustrates that patent protection and affordability are connected policy concerns, although Section 3(d) is not itself a cost-utility test.

Sci API+1

9.6 Bayer Corporation v. Union of India (Natco Pharma compulsory licensing case) (2013), Intellectual Property Appellate Board

Facts:

Natco Pharma sought a compulsory licence for Bayer's patented cancer medicine Nexavar (sorafenib).

Legal issue:

Whether the statutory requirements for compulsory licensing under Section 84 of the Patents Act were satisfied.

Decision:

The Intellectual Property Appellate Board upheld the grant of India's first compulsory licence under Section 84, subject to modification of the royalty rate.

Legal principles:

Reasonable requirements of the public.

Reasonably affordable pricing.

Working of patented inventions in India.

Public interest in pharmaceutical access.

Relevance to biologics:

The case is important when considering whether patent exclusivity and high prices restrict access to essential biological medicines.

However, Nexavar is a small-molecule drug, not a biologic. The case therefore provides an analogous pharmaceutical-access precedent rather than a direct ruling on biologics or QALYs.

WIPO+1

10. Application of CUA to Different Categories of Biologics

Lijek koji "topi" opasan rak pokazao odlične rezultate: "Nije potrebna kemoterapija" - Index.hr

A. Monoclonal antibodies

Used in cancer, autoimmune and inflammatory diseases.

CUA evaluates survival benefits, reduced disease progression, treatment-related adverse effects and quality-of-life improvements.

Human Insulin Injection BP (Soluble / Regular) 100 IU/mL (rDNA origin) | CPHI Online

B. Recombinant proteins

Examples include insulin and certain therapeutic proteins.

Evaluation considers disease control, complications, treatment convenience and long-term healthcare costs.

Organon gets EU approval for POHERDY biosimilar | OGN Stock News

C. Biosimilars

CUA evaluates the economic consequences of switching from reference biologics to biosimilars, including acquisition savings, administration costs and relevant clinical outcomes.

Roswell Park GMP Engineering & Cell Manufacturing Facility | Roswell Park Comprehensive Cancer Center - Buffalo, NY

D. Advanced biological therapies

Certain gene and cell therapies involve substantial upfront expenditure.

Evaluation must account for possible long-term benefits, uncertainty about durability, treatment-related risks and future healthcare costs.

11. Legal Problems Associated with Cost-Utility Analysis

11.1 Conflict between affordability and the right to health

An expensive biological medicine may provide substantial clinical benefits but remain inaccessible to economically disadvantaged patients.

This creates a conflict between limited healthcare budgets and the constitutional and ethical responsibility to promote equitable healthcare access.

11.2 QALY discrimination

Conventional QALY calculations may raise concerns about discrimination against:

Persons with disabilities.

Elderly patients.

Patients with chronic illnesses.

Persons with rare diseases.

Patients with severe pre-existing conditions.

A decision-maker must not mechanically interpret lower projected QALY gains as lower human worth.

11.3 Uncertainty in clinical evidence

Some biological medicines receive regulatory authorization before extensive long-term outcome data become available.

Economic evaluations must account for uncertainty through sensitivity analysis, scenario modelling and post-market evidence.

11.4 Patent monopolies and market concentration

Patent exclusivity can limit competition and influence medicine prices.

The challenge is to protect genuine pharmaceutical innovation without creating unjustifiable barriers to affordable treatment.

11.5 Biosimilar substitution

The economic benefits of biosimilars must be assessed alongside regulatory comparability, immunogenicity, pharmacovigilance and appropriate clinical monitoring.

11.6 Transparency and conflicts of interest

Economic evaluations may be influenced by:

Pharmaceutical industry sponsorship.

Selective clinical-data publication.

Inappropriate comparator selection.

Unrealistic treatment-duration assumptions.

Unjustified utility estimates.

Inadequate disclosure of modelling assumptions.

Transparent methodology and independent assessment are therefore essential.

12. Relationship Between Cost-Utility Analysis and Budget Impact Analysis

CUA and Budget Impact Analysis (BIA) are complementary but different economic evaluation methods.

Indian methodological guidelines recommend using BIA alongside cost-effectiveness evidence rather than treating it as a substitute for economic evaluation.

PMC

13. Hypothetical Case Study: Biological Medicine for Cancer

Consider a hypothetical government healthcare programme evaluating a new monoclonal antibody for cancer patients.

Calculation:

\[ ICER=\frac{8,00,000-2,00,000}{3.5-2.0} \]

\[ ICER=₹4,00,000/QALY \]

Interpretation:

The biological treatment requires an additional expenditure of ₹4 lakh for each additional QALY gained.

A government healthcare authority must then consider:

Whether the clinical improvement is sufficiently substantial.

Whether the expenditure is affordable.

Whether alternative treatments are available.

Whether biosimilar alternatives could reduce costs.

Whether vulnerable patients require additional protection.

Whether public funds could produce greater overall health benefits elsewhere.

This is an illustrative economic model, not an actual clinical or reimbursement recommendation.

14. Future Development of Cost-Utility Law

The development of biological medicines is likely to create new legal questions concerning economic evaluation.

Important emerging areas include:

A. AI-based pharmacoeconomic modelling: Artificial intelligence may assist in predicting treatment outcomes, patient survival and long-term healthcare expenditure. Its assumptions and outputs must remain auditable.

B. Real-world evidence regulation: Healthcare authorities may increasingly use hospital records, patient registries and post-marketing evidence to validate the economic value of biological medicines.

C. Outcome-based reimbursement: Pharmaceutical companies may receive payment based partly on actual patient outcomes rather than simply the quantity of medicine supplied.

D. Value-based pricing: Biological medicine prices may be negotiated with reference to clinical effectiveness, treatment duration, therapeutic innovation and comparative economic value.

E. Biosimilar competition law: Regulatory and competition authorities may need to address exclusionary practices, unjustified patent extensions and barriers to biosimilar market entry.

F. Equity-adjusted QALYs: Future healthcare policies may incorporate disease severity, socioeconomic disadvantage and unmet medical needs into economic evaluations.

15. Recommendations for a Stronger Indian Legal Framework

A comprehensive Indian framework for biological-medicine evaluation should incorporate the following reforms:

1. Standardized economic evaluation: Establish consistent CUA methodologies for innovative biologics, biosimilars and advanced therapies.

2. Transparent pricing: Require appropriate disclosure of medicine acquisition costs, administration expenses and relevant economic assumptions.

3. Independent assessment: Strengthen HTAIn's capacity to conduct independent clinical and economic evaluations.

4. Patient participation: Include patient organizations and healthcare professionals in appraisal and reimbursement decisions.

5. Protection against discrimination: Ensure that QALY-based decisions do not automatically disadvantage disabled persons, elderly patients or persons with rare diseases.

6. Biosimilar development: Encourage scientifically appropriate biosimilar competition to improve affordability.

7. Periodic reassessment: Re-evaluate biological medicines when new clinical evidence, price changes or biosimilar alternatives become available.

8. Reasoned funding decisions: Require public authorities to explain the clinical, economic and distributive reasons behind decisions concerning access to expensive biological treatments.

9. Budget-impact safeguards: Assess the financial consequences of introducing high-cost biological medicines into public healthcare programmes.

10. Constitutional accountability: Ensure that economic rationing decisions remain consistent with Articles 14, 21 and 47 of the Constitution.

16. Conclusion

Cost-Utility Analysis of Biologics represents an important intersection of pharmaceutical regulation, healthcare economics, constitutional law, intellectual property rights and distributive justice.

Its significance lies in determining whether the additional expenditure associated with biological medicines produces meaningful improvements in patient survival and quality of life.

The Indian healthcare system requires an approach that balances three fundamental objectives:

Innovation: Encouraging research, biotechnology development and pharmaceutical investment.

Affordability: Ensuring that biological medicines are financially accessible.

Equity: Preventing economic evaluation from becoming an instrument of arbitrary healthcare exclusion.

The decisions in Rogers v. Swindon NHS Primary Care Trust, Paschim Banga Khet Mazdoor Samity, Novartis AG v. Union of India and Bayer Corporation v. Union of India provide important legal principles concerning biological treatment access, constitutional healthcare obligations and pharmaceutical affordability.

Ultimately, cost-utility analysis should not determine the value of human life. It should help healthcare institutions make scientifically informed, economically responsible, transparent and constitutionally defensible decisions about the allocation of limited healthcare resources.

17. Important Legal and Academic References

For further academic research, the following materials are particularly useful:

Indian Reference Case for undertaking Economic Evaluation for Health Technology Assessment. Read the research paper.

Health Technology Assessment in India (HTAIn). Official government framework.

National Methodological Guidelines for Budget Impact Analysis in India. Read the guidelines.

Guidelines on Similar Biologics: Regulatory Requirements for Marketing Authorization in India, 2016.

Rogers v. Swindon NHS Primary Care Trust [2006] EWCA Civ 392.

Servier Laboratories Ltd v NICE [2009] EWHC 281 (Admin).

Paschim Banga Khet Mazdoor Samity v State of West Bengal (1996) 4 SCC 37.

Novartis AG v Union of India (2013) 6 SCC 1.

Bayer Corporation v Union of India (Natco compulsory licensing decision, 2013).

Central academic proposition: Cost-Utility Analysis of Biologics should be understood not merely as pharmaceutical cost accounting but as a legal and ethical framework for balancing therapeutic innovation, economic efficiency, public health obligations and distributive justice.